Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus
This study will compare the impact of including exenatide once weekly in addition to usual care vs. usual care without exenatide on major cardiovascular outcomes as measured by the primary composite endpoint of…
- Trial name
- NCT01144338
- Testing
- Exenatide Once Weekly
- Where
- 629 sites in United States, Argentina and 33 more
- Volunteers
- 14,752 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A PK-PD Study of PSN821 in Type 2 Diabetes Patients (T2DM)
The purpose of this study is to investigate the pharmacokinetics and pharmacodynamics of PSN821 in patients with type 2 diabetes.
- Trial name
- NCT01386099
- Testing
- PSN821
- Where
- 4 sites in South Africa
- Volunteers
- 66 people
- Sponsor
- Prosidion Ltd.
Type 2 Diabetes
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2…
- Trial name
- TELOS (NCT06972732)
- Testing
- Metformin, Dapagliflozin/Pioglitazone, Dapagliflozin/Sitagliptin
- Where
- South Korea
- Volunteers
- 204 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Type II Diabetes Mellitus
A Study of Different Doses of Sitagliptin (MK-0431) in Participants With Type 2 Diabetes Mellitus (MK-0431-014)
A study of different doses of MK-0431 in participants with type 2 diabetes mellitus. There have been 3 extensions to the base study (Extension 1: up to Week 52, Extension 2: up to Week 106, and Extension 3: up to Week 158).
- Trial name
- NCT00481663
- Testing
- Sitagliptin, Metformin, Rescue
- Volunteers
- 555 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Efficacy and Safety of Twice-Daily Insulin Lispro Low Mixture Compared to a Once-Daily Long Acting Insulin Comparator in Patients Who Have Been Using One or More Oral Antihyperglycemic Agents Without Insulin
The purposes of this study are to determine: 1. If patients taking insulin lispro LM with metformin will have better overall control of their blood sugar than patients taking a long acting insulin comparator with metformin. 2.
- Trial name
- NCT00036504
- Testing
- Insulin Lispro low mixture
- Where
- 13 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
A Study to Evaluate P-Glucose, Safety and Tolerability After Oral Single Dosing of AZD6370 in Type 2 Diabetic Patients
The purpose of this study is to assess the effect of AZD6370 on blood sugar and to study safety and tolerability in patients with type 2 diabetes.
- Trial name
- NCT00690287
- Testing
- AZD6370
- Where
- 3 sites in Sweden
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Comparison of Biphasic Insulin Aspart 30 Twice Daily With Two Different Initial Dosage Split Regimens in Subjects With Type 2 Diabetes: An Extension to Trial BIASP-3756
This trial is conducted in Asia. The aim of the trial is to compare the effect on glycaemic control of biphasic insulin aspart 30 twice daily with two different dosage split regimens for Chinese subjects with type 2 diabetes who…
- Trial name
- NCT01278160
- Testing
- biphasic insulin aspart 30, metformin
- Where
- China
- Volunteers
- 179 people
- Sponsor
- Novo Nordisk A/S
Diabetes Type 2
Effect of DMMET-01 on Insulin Sensitivity in Naive Type 2 Diabetes Patients (CLAMP)
The aim of this study is to determine the effect of DMMET-01 on insulin sensitivity by Glucose CLAMP technique in Mexican type 2 diabetes patients, after 2 months of treatment.
- Trial name
- DMMETclamp (NCT00940797)
- Testing
- DMMET-01
- Where
- Mexico
- Volunteers
- 20 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Type 2 Diabetes Mellitus (T2DM)
Sitagliptin Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus
A clinical study to determine the safety and efficacy of sitagliptin in patients with Type 2 Diabetes Mellitus who have inadequate glycemic (blood sugar) control on metformin therapy.
- Trial name
- NCT00337610
- Testing
- sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day
- Volunteers
- 190 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BI 10773 in Type II Diabetes Patients With Different Degrees of Renal Impairment
Assessment of the effect of normal and impaired kidney function on the pharmacokinetics, pharmacodynamics and safety of BI 10773
- Trial name
- NCT01907113
- Testing
- BI 10773
- Where
- 2 sites in Germany
- Volunteers
- 40 people
- Sponsor
- Boehringer Ingelheim
Endothelial Dysfunction, Diabetes Mellitus
Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients
The Purpose of this study was to evaluate the effect of the combination glimepiride/metformin over endothelial dysfunction (ED) in asymptomatic patients with type 2 diabetes mellitus (DM) using 13N-ammonia-positron emission…
- Trial name
- NCT01429818
- Testing
- Glimepiride/metformin, Metformin
- Where
- Mexico
- Volunteers
- 16 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Diabetes Mellitus, Type 2, Acute Coronary Syndrome
Cardiovascular Outcomes Study of Alogliptin in Patients With Type 2 Diabetes and Acute Coronary Syndrome
The purpose of this study is to evaluate the cardiovascular outcomes of alogliptin, once daily (QD), compared with placebo, in addition to standard of care, in patients with type 2 diabetes mellitus and acute coronary syndrome.
- Trial name
- EXAMINE (NCT00968708)
- Testing
- Alogliptin
- Where
- 908 sites in United States, Argentina and 48 more
- Volunteers
- 5,380 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes
The Revita DMR Post Market Pilot Clinical Registry is a post-market, prospective, observational, noninterventional clinical registry in patients with T2D in Germany undergoing the Revita Procedure with the CE marked Revita System…
- Trial name
- NCT06256497
- Testing
- Duodenal Mucosal Resurfacing (DMR)
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Fractyl Health Inc.
Type 2 Diabetes Mellitus, High HbA1c Level
Evaluation of Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Background Combination of Metformin and Sulfonylurea
This study intends to compare the efficacy and safety of dapagliflozin versus placebo in patients with type 2 diabetes who have inadequate glycaemic control on a background combination of metformin and sulfonylurea.
- Conditions
- Type 2 Diabetes Mellitus, High HbA1c Level, Inadequate Glycaemic Control
- Trial name
- NCT01392677
- Testing
- dapagliflozin
- Where
- 42 sites in Canada, Czechia and 4 more
- Volunteers
- 311 people
- Sponsor
- AstraZeneca
Essential Hypertension, Type 2 Diabetes Mellitus
A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy
The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus
- Trial name
- NCT06220773
- Testing
- BR1019A, BR1019B, BR1019C
- Where
- 3 sites in Indonesia, South Korea
- Volunteers
- 276 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Painful Diabetic Neuropathy
Safety and Efficacy of EMA401 in Patients With Painful Diabetic Neuropathy (PDN)
The purpose of this study is to evaluate safety and efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN).
- Trial name
- EMPADINE (NCT03297294)
- Testing
- EMA401
- Where
- 64 sites in Australia, Austria and 14 more
- Volunteers
- 142 people
- Sponsor
- Novartis Pharmaceuticals
Hypercortisolism, Diabetes Mellitus, Type 2
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%)…
- Trial name
- NCT05772169
- Testing
- Mifepristone 300 MG [Korlym]
- Where
- 36 sites in United States
- Volunteers
- 1,113 people
- Sponsor
- Corcept Therapeutics
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®
This study is conducted in Asia. The aim of this post marketing surveillance (PMS) is to assess safety and effectiveness of long-term treatment with Tresiba® (insulin degludec) in patients with diabetes mellitus requiring insulin…
- Trial name
- NCT01984372
- Testing
- insulin degludec
- Where
- Japan
- Volunteers
- 6,163 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Comparison of Insulin Mix25 Versus Mix50
The purpose of this study is to determine the efficacy and safety of insulin Lispro Mix25 (LM25) compared to insulin Lispro Mix50 (LM50) as an insulin starter in participants with Type 2 diabetes mellitus (T2DM).
- Trial name
- CLASSIFY (NCT01773473)
- Testing
- Insulin Lispro Mix25, Insulin Lispro Mix50
- Where
- 27 sites in China, Japan and 2 more
- Volunteers
- 403 people
- Sponsor
- Eli Lilly and Company
Chronic Kidney Disease, Type 2 Diabetes
A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease
The purpose of this study is to evaluate the efficacy of ASP8232 in reducing Urinary Albumin to Creatinine Ratio (UACR) in subjects with Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) at 12 weeks compared to…
- Trial name
- ALBUM (NCT02358096)
- Testing
- ASP8232
- Where
- 57 sites in Czechia, Denmark and 7 more
- Volunteers
- 125 people
- Sponsor
- Astellas Pharma Europe B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.